Loading stock data…
NRIX
$16.98+0.17 (+1.01%)
Market OpenUpdated 3:07 PM EDT
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nurix Therapeutics, Inc. in the Healthcare sector is trading at $16.98. The stock is currently 25% below its 52-week high of $22.50, remaining 20.3% above its 200-day moving average. Technical signals show neutral RSI of 57 and bullish MACD crossover, explaining why NRIX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.98
Potential Upside
5%
Whystock Fair Value$17.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Mean target$30.24+78.1%
Range$23.00 – $41.00
Fundamentals
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.73B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.11%
Volume
Today's trading volume
313,851
Recent News
Nurix Therapeutics Inc. (NRIX): Leadership in Targeted Protein Degradation Attracts Smart Money
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Nurix Therapeutics, Inc. (NASDAQ:NRIX) ranks 2nd on this list. Elite managers are piling into Nurix Therapeutics, Inc. (NASDAQ:NRIX) stock to capitalize on its leadership in Targeted Protein Degradation (TPD), a field many believe is the next frontier of medicine. A […]
Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best low priced biotech stocks to invest in. Wells Fargo cut the price target on Nurix Therapeutics, Inc. (NASDAQ:NRIX) to $28 from $29 on April 9, maintaining an Overweight rating on the shares and stating that although management is continuing execution on bexdeg’s chronic lymphocytic leukemia trials […]
Did Sanofi Revenue Expiry and Rising R&D Spend Just Recast Nurix Therapeutics' (NRIX) Investment Narrative?
Nurix Therapeutics, Inc. has reported past first-quarter 2026 results showing revenue of US$6.25 million versus US$18.45 million a year earlier, alongside a wider net loss of US$87.17 million and a higher loss per share. The update underscores how the end of Sanofi’s initial research term sharply reduced collaboration revenue just as Nurix increased spending to advance bexobrutideg and its broader protein degradation pipeline. Next, we’ll examine how the revenue drop tied to Sanofi’s...
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nurix Therapeutics (NRIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Company News for Apr 9, 2026
Companies in The News Are: DAL,RPM,NRIX,LEVI